Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

robatumumab

A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Robatumumab binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; downregulation of this survival pathway may result in the induction of apoptosis and decreased cellular proliferation. The activation of IGF-1R, a tyrosine kinase and a member of the insulin receptor family, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-IGF-1R recombinant monoclonal antibody SCH 717454
Code name:SCH 717454
Chemical structure:immunoglobulin G1, anti-(human insulin-like growth factor I receptor) (human monoclonal SCH 717454 heavy chain), disulfide with human monoclonal SCH 717454 light chain, dimer
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search